Cited by 745Liver Disease Diagnosis and TreatmentDiet, Metabolism, and DiseaseDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 261 of the 263 references it cites were found in a registry or an index.

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Open access

Samuel, Varman T., Shulman, Gerald I.·2018·Cell Metabolism

DOI 10.1016/j.cmet.2017.08.002PMC PMC5762395

Open this paper in CoChat — free account Open PDF

Abstract

NAFLD is closely linked with hepatic insulin resistance. Accumulation of hepatic diacylglycerol activates PKC-ε, impairing insulin receptor activation and insulin-stimulated glycogen synthesis. Peripheral insulin resistance indirectly influences hepatic glucose and lipid metabolism by increasing flux of substrates that promote lipogenesis (glucose and fatty acids) and gluconeogenesis (glycerol and fatty acid-derived acetyl-CoA, an allosteric activator of pyruvate carboxylase). Weight loss with diet or bariatric surgery effectively treats NAFLD, but drugs specifically approved for NAFLD are not available. Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/δ, FXR and analogs for FGF-21, and GLP-1). Others specifically inhibit key enzymes involved in lipid synthesis (e.g., mitochondrial pyruvate carrier, acetyl-CoA carboxylase, stearoyl-CoA desaturase, and monoacyl- and diacyl-glycerol transferases). Finally, a novel class of liver-targeted mitochondrial uncoupling agents increases hepatocellular energy expenditure, reversing the metabolic and hepatic complications of NAFLD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.cmet.2017.08.002

Cites

261 of 261 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,720
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416 · cited 1×
“A common SNP (rs738409, I148M) in the lipid droplet protein patatin-like phospholipase domain-containing protein 3 (PNLPA3, also called adiponutrin) has been associated with NAFLD and fibrosis (Romeo et al., 2008; Singal et al., 2014).”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Nonetheless, pioglitazone did improve several discrete metrics of hepatic inflammation (Sanyal et al., 2010).”
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Aminian, A., Brethauer, S. A., Navaneethan, S. D., Singh, R. P., Pothier, C. E., Nissen, S. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1600869 · Cited by 2,934
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874 · cited 1×
“Perspective These include 3-phosphoinositide-dependent kinase-1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al., 1997; Guertin and Sabatini, 2007; Stephens et al., 1998).”
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · cited 2×
“and mechanistic target of rapamycin complex 2 (mTORC2) (Guertin and Sabatini, 2007), which converge on Akt phosphorylation (Alessi et al.”
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Self-citation

Flagged first, then by citations

Show all 263 references

2 of the 263 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 743

Complying with the physiological functions of Golgi apparatus for secretory exocytosis facilitated oral absorption of protein drugs
Xing, L., Zheng, Y., Yu, Y., Wu, R., Liu, X., Zhou, R., & Huang, Y. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02848g · Cited by 20
The efficacy and safety of acupuncture in nonalcoholic fatty liver disease
Chen, P., Zhong, X., Dai, Y., Tan, M., Zhang, G., Ke, X., Huang, K., & Zhou, Z. (2021) · Medicine · doi:10.1097/md.0000000000027050 · Cited by 20
The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population
Yuan, F., Gu, Z., Bi, Y., Yuan, R., Niu, W., Ren, D., Zhang, L., He, G., & Liu, B. (2022) · Aging · doi:10.18632/aging.203970 · Cited by 20
ERα-Dependent Regulation of Adropin Predicts Sex Differences in Liver Homeostasis during High-Fat Diet
Meda, C., Dolce, A., Vegeto, E., Maggi, A. C., & Torre, S. D. (2022) · Nutrients · doi:10.3390/nu14163262 · Cited by 23
Assessing the in vivo ameliorative effects of Lactobacillus acidophilus KLDS1.0901 for induced non-alcoholic fatty liver disease treatment
Wang, Y., Wang, Z., Wan, Y., Jin, F., Shi, X., Xing, Z., Tian, B., & Li, B. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1147423 · Cited by 20
“Soaring obesity rates have been closely linked to noncommunicable metabolic diseases like chronic liver and cardiovascular diseases as approximately 90% of patients are diagnosed with severe obesity and non-alcoholic fatty liver disease (NAFLD) (1, 2).”
Background
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 20
“acetyl-CoA carboxylase [ACC], fatty acid synthase [FAS], stearoyl-CoA desaturase [SCD1] and DGAT2) are involved in de novo lipogenesis in the liver [222]”
Background
Epithelial Transport in Disease: An Overview of Pathophysiology and Treatment
Clemente‐Suárez, V. J., Martín-Rodríguez, A., Redondo-Flórez, L., Villanueva-Tobaldo, C. V., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2023) · Cells · doi:10.3390/cells12202455 · Cited by 24
“NAFLD is associated with insulin resistance, which impairs the transport of glucose and lipids in the NAFLD is associated with insulin resistance, which impairs the transport of glucose and lipids in the liver [69]. liver [69].”
Background
Overview of pyroptosis mechanism and in-depth analysis of cardiomyocyte pyroptosis mediated by NF-κB pathway in heart failure
Zhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117367 · Cited by 22
Obesity, adipocyte hypertrophy, fasting glucose, and resistin are potential contributors to nonalcoholic fatty liver disease in South Asian women
Albracht‐Schulte, K., Rosairo, S., Ramalingam, L., Wijetunge, S., Ratnayake, C., Kotakadeniya, H. M. S. R. B., Dawson, J., Kalupahana, N. S., & Moustaïd‐Moussa, N. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s203937 · Cited by 23
“CRP, which is strongly associated with central obesity in South Asians,50 was identified as a weak predictor of NAFLD.51 Accordingly, others have also reported no difference in hsCRP with NAFLD.52 Taking into account the insignificant findings regarding inflammation and AGT as well as enzymes for liver health, includi…”
BackgroundInfluential
Role of the PNPLA3 polymorphism rs738409 on silymarin + vitamin E response in subjects with non-alcoholic fatty liver disease
Aller, R., Laserna, C., Rojo, M. Á., Mora, N., Sánchez, C. G., Pina, M. J. B., Sigüenza, R., Dur�, M., Primo, D., Izaola, O., et al. (2018) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2018.5602/2018 · Cited by 19
“Insulin resistance (IR) and metabolic syndrome (MS) represent the underlying physiopathological substrate in most patients with NAFLD (3).”
Background
The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
Perakakis, N., Joshi, A., Peradze, N., Stefanakis, K., Li, G., Feigh, M., Veidal, S. S., Rosen, G., Fleming, M., & Mantzoros, C. S. (2020) · Hepatology Communications · doi:10.1002/hep4.1558 · Cited by 19
“(46) PPARα/γ or pan-PPAR agonists may be effective but are associated with more severe side effects, mainly due to the full PPARγ agonism.(46) Additionally, dual or triple agonism through one single medication offers less flexibility for dose adjustments, which makes it more challenging to achieve the right balance be…”
Background
Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma
Feng, N., Du, X.-Y., Zhang, Y.-S., Jiao, Z.-K., Wu, X., & Yang, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1061091 · Cited by 20
“Moreover, these PPAR members were critical transcription factors regulating mitochondrial functions and energy homeostasis (49); thus, some pharmacological strategies of PPAR agonists have emerged and are associated with improved clinical outcomes (50).”
Background
MBOAT7-driven lysophosphatidylinositol acylation in adipocytes contributes to systemic glucose homeostasis
Massey, W. J., Varadharajan, V., Banerjee, R., Brown, A. L., Horak, A. J., Hohe, R. C., Jung, B. M., Qiu, Y., Chan, E. R., Pan, C., et al. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100349 · Cited by 19
Loss of LBP triggers lipid metabolic disorder through H3K27 acetylation-mediated C/EBPβ-SCD activation in non-alcoholic fatty liver disease
Zhu, Y., 安徽医科大学基础医学院病理生理学系, 安. 合. 2., Meng, L.-L., Ma, J.-H., Yuan, X., Chen, S., Yi, X., Li, X., Wang, Y., Tang, Y., et al. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2023.022 · Cited by 19
Metabolic dysfunction–associated steatotic liver disease, hypertriglyceridaemia, and cardiovascular risk
Gurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Extract of Schisandra chinensis fruit protects against metabolic dysfunction in high‐fat diet induced obese mice via FXR activation
Gu, M., Song, H.-Y., Li, Y., Jiang, Y.-W., Zhang, Y.-L., Tang, Z., Ji, G., & Huang, C. (2020) · Phytotherapy Research · doi:10.1002/ptr.6743 · Cited by 14
“The fatty liver is associated with obesity and IR (Samuel & Shulman, 2018).”
Background
Temporal dynamics of the multi-omic response to endurance exercise training across tissuesPreprint
MoTrPAC Study Group, Amar, D., Gay, N. R., Beltran, P. M. J., Adkins, J., Armenteros, J. J. A., Ashley, E. A., Ávila-Pacheco, J., Bae, D., Bararpour, N., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.21.508770 · Cited by 19
“Moreover, although unrelated to exercise, it has been proposed that mitochondrial dysfunction is a key component of NAFLD progression 134 .”
Background
Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value
Wang, L., Wang, H., Wu, J., Ji, C., Wang, Y., Gu, M., Li, M., & Yang, H. W. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1635638 · Cited by 18
Pathogenesis of metabolic dysfunction-associated steatotic liver disease and donor liver damage
Gou, C., Zhang, W., Xu, H., Zhang, H., Ding, R., & Zhang, X. (2025) · iLiver · doi:10.1016/j.iliver.2025.100195 · Cited by 22
“38 Excessive intake of fatty acids, particularly saturated fatty acids, significantly increases the degree of hepatic steatosis.”
Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study
Xia, F., Wang, H., Ye, T., Fu, X.-L., Tan, X., Zeng, Y., Fan, J., & Xu, Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01518-5 · Cited by 18
The pathogenesis of liver cancer and the therapeutic potential of bioactive substances
Gao, S., Jiang, X., Wang, L., Jiang, S., Luo, H., Chen, Y., & Peng, C. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1029601 · Cited by 18
“, 2021) and encompasses a range of pathological changes, including steatosis, NASH, fibrosis, and cirrhosis (Samuel and Shulman, 2018).”
Background
Emerging role of lipophagy in liver disorders
Nazeer, B., Khawar, M. B., Khalid, M. U., Hamid, S. E., Rafiq, M., Abbasi, M. H., Sheikh, N., Ali, A. H., Fatima, H., & Ahmad, S. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04707-1 · Cited by 18
“Lipogenesis and insulin resistance are disclosed by NAFLD [, 45, 46].”
Probiotic yogurt regulates gut microbiota homeostasis and alleviates hepatic steatosis and liver injury induced by high‐fat diet in golden hamsters
Zhu, L., Ying, N., Hao, L., Fu, A., Ding, Q., Cao, F., Ren, D., Han, Q., & Li, S. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.3930 · Cited by 17
The central role of mitochondrial metabolism in hepatic steatosis
Win, S., Than, T. A., Kaplowitz, N., Wong, N., Arya, A., Win, Z. T., Win, S. H., Phyu, E., Kuemerle, C., Suh, J., et al. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00039 · Cited by 18
Zexie-Baizhu Decoction ameliorates non-alcoholic fatty liver disease through gut-adipose tissue crosstalk
Shi, J., Liu, Y., Zhang, Z., Zhong, X., Cao, Y., Ni, H., He, Q., Wang, Z., Liu, Y., Chen, Q., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118700 · Cited by 18
Rosiglitazone reverses high fat diet-induced changes in BMAL1 function in muscle, fat, and liver tissue in mice
Ribas‐Latre, A., Fekry, B., Kwok, C., Baumgartner, C., Shivshankar, S., Sun, K., Chen, Z., & Eckel‐Mahan, K. L. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0090-5 · Cited by 18
“Abnormal hepatic lipid deposition is thought to be a key component of insulin resistance in the liver [29].”
European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale
Mann, J. P., Vreugdenhil, A. C. E., Socha, P., Jańczyk, W., Baumann, U., Rajwal, S. R., Casswall, T., Marcus, C., van Mourik, I., O’Rahilly, S., et al. (2018) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.003 · Cited by 17
Liver-specific insulin receptor isoform A expression enhances hepatic glucose uptake and ameliorates liver steatosis in a mouse model of diet-induced obesity
López‐Pastor, A. R., Gómez‐Hernández, A., Díaz-Castroverde, S., González‐Aseguinolaza, G., Gonzalez-Rodriguez, A., Garcia, G., Fernández, S., Escribano, Ó., & Benito, M. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.036186 · Cited by 18
“This enzyme also has a crucial role in fatty acid synthesis and it has been previously described that decreased hepatic expression of Acaca improves fatty liver profile (Samuel and Shulman, 2018).”
Causative and Sanative dynamicity of ChREBP in Hepato-Metabolic disorders
Daniel, P. V., & Mondal, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151128 · Cited by 18
Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
Parameswaran, M., Hasan, H. A., Sadeque, J., Jhaveri, S., Avanthika, C., Arisoyin, A. E., Dhanani, M., & Rath, S. M. (2021) · Cureus · doi:10.7759/cureus.20776 · Cited by 21
“Insulin resistance leads to increased lipolysis in dysfunctional adipose tissue and reduced glucose uptake in skeletal muscle [27,28].”
Background
When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
Rojano‐Toimil, A., Rivera‐Esteban, J., Manzano-Núñez, R., Bañares, J., Selva, D. M., Gabriel-Medina, P., Ferrer, R., Pericàs, J. M., & Ciudin, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123286 · Cited by 20
Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity
Larsen, F. T., Hansen, D., Terkelsen, M. K., Bendixen, S. M., Avolio, F., Wernberg, C. W., Lauridsen, M. M., Grønkjær, L. L., Jacobsen, B. G., Gammelmark, E., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100615 · Cited by 17
“Dyslipidaemia-related cardiovascular disease is the leading cause of death in patients with NASH 52,53 and atherosclerosis-related ﬁ brosis 54 may contribute to elevated plasma SMOC2 levels in NASH.”
Non-Alcoholic Fatty Liver Disease (NAFLD) Management in the Community
Park, Y. B., Ko, K. S., & Rhee, B. D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062758 · Cited by 19
Key Signals Produced by Gut Microbiota Associated with Metabolic Syndrome, Cancer, Cardiovascular Diseases, and Brain Functions
Dicks, L. M. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110539 · Cited by 20
“Excess TAG stored in adipose tissue in muscle, and the liver leads to an increase in lipotoxic intermediates such as diacylglycerol (DAG) [43] and ceramide, ultimately leading to insulin resistance [44].”
Hepatocyte-specific PKCβ deficiency protects against high-fat diet-induced nonalcoholic hepatic steatosis
Shu, Y., Hassan, F., Coppola, V., Baskin, K. K., Han, X., Mehta, N. K., Ostrowski, M. C., & Mehta, K. D. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101133 · Cited by 17
Identification of metabolic biomarkers associated with nonalcoholic fatty liver disease
Jiang, H., Hu, Y., Zhang, Z., Chen, X., & Gao, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01911-2 · Cited by 17
“However, there were significant challenges in addressing the global epidemic of NAFLD, metabolic, and hepatic complications [23].”
Background
TFEB activator tanshinone IIA and derivatives derived from Salvia miltiorrhiza Bge. Attenuate hepatic steatosis and insulin resistance
Zheng, L., Li, B., Yuan, A., Bi, S., Puscher, H., Liu, C., Qiao, L., Qiao, Y., Wang, S., & Zhang, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118662 · Cited by 18
Camu-camu decreases hepatic steatosis and liver injury markers in overweight, hypertriglyceridemic individuals: A randomized crossover trial
Agrinier, A.-L., Morissette, A., Daoust, L., Gignac, T., Marois, J., Varin, T. V., Pilon, G., Larose, É., Gagnon, C., Desjardins, Y., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101682 · Cited by 20
Global 13C tracing and metabolic flux analysis of intact human liver tissue ex vivo
Grankvist, N., Jönsson, C., Hedin, K., Sundqvist, N., Sandström, P., Björnsson, B., Begzati, A., Mickols, E., Artursson, P., Jain, M., et al. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01119-3 · Cited by 17
“Metabolic dysfunction-associated steatotic liver disease (formerly non-alcoholic fatty liver disease) is a common feature of these disorders, which can trigger liver inflammation and lead to advanced liver disease, through mechanisms that still are not fully understood 1 .”
Background
Protective Effect of a Mixture of Astragalus membranaceus and Lithospermum erythrorhizon Extract against Hepatic Steatosis in High Fat Diet‐Induced Nonalcoholic Fatty Liver Disease Mice
Choi, D. J., Kim, S. C., Park, G. E., Choi, B.-R., Lee, D., Lee, Y., Park, S.-B., Park, Y. I., & Kim, G. S. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/8370698 · Cited by 17
“1e liver is the major contributor to whole-body lipogenesis, gluconeogenesis, and cholesterol metabolism [2, 3].”
Background
The advantages of physical exercise as a preventive strategy against NAFLD in postmenopausal women
Molina‐Molina, E., Furtado, G. E., Jones, J. G., Portincasa, P., Pedrosa, A., Teixeira, A. M., Barros, M. P., Bachi, A. L. L., & Sardão, V. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13731 · Cited by 19
Physiology of the Wildland Firefighter: Managing Extreme Energy Demands in Hostile, Smoky, Mountainous Environments
Ruby, B. C., Coker, R. H., Sol, J., Quindry, J. C., & Montain, S. J. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220016 · Cited by 31
“Whether these changes are potentially heightening the seasonal risk of developing insulin resistance and metabolic diseases during wildland fire operations remains unknown (110).”
Structural characterization of a α-d-glucan from Ginkgo biloba seeds and its protective effects on non-alcoholic fatty liver disease in mice
Liang, S., Yao, Z., Chen, J., Jin, Q. Y., Dai, Y., & Li, H. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.123022 · Cited by 16
Intelligent Nano‐Cage for Precision Delivery of CRISPR‐Cas9 and ACC Inhibitors to Enhance Antitumor Cascade Therapy Through Lipid Metabolism Disruption
Zhao, W., La, Z., Guo, J., Xu, Q., Zhang, M., Liu, H., Ren, C., Zhao, Y., Wang, J., Peng, Q., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202418090 · Cited by 17
Conjugated Lithocholic Acid Activates Hepatic TGR5 to Promote Lipotoxicity and MASLD‐MASH Transition by Disrupting Carnitine Biosynthesis
Lian, S., Lu, M., Jiajing, L., Zhang, B., Fang, Y., Wang, X., Zheng, M., Ni, Y., Xu, G., Yang, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202410602 · Cited by 17
Are the polyol pathway and hyperuricemia partners in the development of non‐alcoholic fatty liver disease in diabetes?
Hotta, N., Kawamura, T., & Umemura, T. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13190 · Cited by 16
High-starchy carbohydrate diet aggravates NAFLD by increasing fatty acids influx mediated by NOX2
Gao, Y., Hua, R., Peng, K., Yin, Y., Zeng, C., Guo, Y., Wang, Y., Li, L., Li, X., Qiu, Y., et al. (2022) · Food Science and Human Wellness · doi:10.1016/j.fshw.2022.10.026 · Cited by 16
Si-Ni-San Reduces Hepatic Lipid Deposition in Rats with Metabolic Associated Fatty Liver Disease by AMPK/SIRT1 Pathway
Zhang, N., Liu, Y., Wang, J., Yingying, X., Zhang, Y., Dai, J., Ma, Z., & Ma, D. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s417378 · Cited by 18
“Many factors affect hepatic lipid deposition, including increased lipid synthesis and impaired fatty acid oxidation.(3) SREBP1c and FAS play critical roles in hepatic lipid synthesis, and overexpressed SREBP-1c and FAS cause hepatic lipid deposition, and then lead to MAFLD.”
BackgroundMethodInfluential
Hyperinsulinaemia: does it tip the balance toward intrahepatic fat accumulation?
Hodson, L., & Karpe, F. (2019) · Endocrine Connections · doi:10.1530/ec-19-0350 · Cited by 16
Extracts of Vine Tea Improve Diet-Induced Non-Alcoholic Steatohepatitis Through AMPK-LXRα Signaling
Chen, Y., Song, H., Zhang, Z., Chen, Q., Tang, Z., & Gu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.711763 · Cited by 15
“Non-alcoholic fatty liver disease (NAFLD) is a metabolic liver disorder of global prevalence (Friedman et al., 2018; Samuel and Shulman, 2018).”
Background
Beneficial effects of Lactobacillus rhamnosus hsryfm 1301 fermented milk on rats with nonalcoholic fatty liver disease
Chen, D., Liang, Y., Liang, J., Shen, F., Cheng, Y., Qu, H., Wa, Y., Guo, C., Gu, R., Qian, J., et al. (2023) · Journal of Dairy Science · doi:10.3168/jds.2022-22383 · Cited by 16
Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
“It is worth noting that the expression and action of various enzymes involved in lipogenesis and fatty acid storage in triglycerides are increased in individuals with NAFLD [16].”
Background
MicroRNA-34a Mediates High-Fat-Induced Hepatic Insulin Resistance by Targeting ENO3
Wang, Y., Zhao, X., Zhang, L., Yang, C., Zhang, K., Gu, Z., Ding, H., Li, S., Qin, J., & Chu, X. (2023) · Nutrients · doi:10.3390/nu15214616 · Cited by 15
“When IR occurs in the liver, the body experiences substantial disturbances in glycolipid metabolism, and thus, hepatic IR is closely associated with many of the metabolic diseases currently plaguing our society, such as nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D) [1,2].”
Background
Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective
Fu, Y., Wang, Z., & Qin, H. (2024) · Metabolites · doi:10.3390/metabo14040218 · Cited by 15
“Targeting glycolysis in the liver may be a potential therapeutic strategy for MAFLD and is important for blocking MAFLD from being more malignant.”
Background
Chemokine (C-C motif) ligand 2 gene ablation protects low-density lipoprotein and paraoxonase-1 double deficient mice from liver injury, oxidative stress and inflammation
Luciano‐Mateo, F., Cabré, N., Fernández‐Arroyo, S., Baiges‐Gayà, G., Hernández‐Aguilera, A., Rodríguez‐Tomàs, E., Mercado-Gómez, M., Menéndez, J. A., Camps, J., & Joven, J. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.03.006 · Cited by 15
Hepatic transcriptome signature correlated with HOMA-IR explains early nonalcoholic fatty liver disease pathogenesis
Chatterjee, A., Basu, A., Das, K., Singh, P., Mondal, D., Bhattacharya, B., Roychoudhury, S., Majumder, P. P., Chowdhury, A., & Basu, P. (2020) · Annals of Hepatology · doi:10.1016/j.aohep.2020.06.009 · Cited by 15
Efficacy of a Novel Herbal Formulation (F2) on the Management of Obesity: In Vitro and In Vivo Study
Pandeya, P. R., Lamichhane, R., Lee, K., Lamichhane, G., Kim, S.-G., & Jung, H. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/8854915 · Cited by 15
“Accumulation of lipid components in the liver activates diacyl glycerol activated protein kinase (PKCε), which further impairs the activation of insulin receptors and insulin-stimulated glycogen synthesis [59, 60].”
Background
Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease
Zheng, J., Wu, H., Zhang, Z., & Yao, S. (2021) · Hereditas · doi:10.1186/s41065-021-00196-8 · Cited by 15
“Some patients with NAFLD eventually developed cirrhosis, fibrosis, or hepatocellular carcinoma [1].”
Background
Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients
Billeter, A. T., Scheurlen, K. M., Israel, B., Straub, B. K., Schirmacher, P., Kopf, S., Nawroth, P. P., & Müller-Stich, B. P. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005631 · Cited by 15
Investigation of FcRn‐Mediated Transepithelial Mechanisms for Oral Nanoparticle Delivery Systems
Yu, Y., Wu, Z., Wu, J., Shen, X., Wu, R., Zhou, M., Li, L., & Huang, Y. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100145 · Cited by 15
Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high‐fat diet
Wang, K., Li, B., Fu, R., Jiang, Z., Wen, X., & Ni, Y. (2022) · Journal of Food Science · doi:10.1111/1750-3841.16076 · Cited by 14
Multi‐omic network analysis identified betacellulin as a novel target of omega‐3 fatty acid attenuation of western diet‐induced nonalcoholic steatohepatitis
Padiadpu, J., García‐Jaramillo, M., Newman, N. K., Pederson, J. W., Rodrigues, R. R., Li, Z., Singh, S. P., Monnier, P., Trinchieri, G., Brown, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202318367 · Cited by 13
“Combining the NASH network with the meta-analysis of liver cancer identifies betacellulin as a key pathogenic regulator of NASH inhibited by DHA NASH can progress to liver cirrhosis and cancer in humans (Samuel & Shulman, 2018; Anstee et al , 2019; Pfister et al , 2021).”
Background
BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes
Alcober-Boquet, L., Kraus, N., Huber, L. S., Vutukuri, R., Fuhrmann, D. C., Stroß, C., Schaefer, L., Scholich, K., Zeuzem, S., Piiper, A., et al. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00413.2023 · Cited by 14
Insulin resistance in NSCLC: unraveling the link between development, diagnosis, and treatment
Zhan, S., Wang, L., Wang, W., & Li, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1328960 · Cited by 14
“This abnormal accumulation contributes to the development of disorders in fatty acid metabolism and further exacerbates insulin resistance (29, 30).”
Background
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis
Foglia, B., Sutti, S., Cannito, S., Rosso, C., Maggiora, M., Casalino, A., Bocca, C., Novo, E., Protopapa, F., Ramavath, N. N., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1342404 · Cited by 16
Adipose‐derived miRNAs as potential biomarkers for predicting adulthood obesity and its complications: A systematic review and bioinformatic analysis
Liu, X., Sun, H., Zheng, L., Zhang, J., Su, H., Li, B., Wu, Q., Liu, Y., Xu, Y., Song, X., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13748 · Cited by 15
Ascorbate protects liver from metabolic disorder through inhibition of lipogenesis and suppressor of cytokine signaling 3 (SOCS3)
Xu, Y., Wu, Y., Xiong, Y., Tao, J., Pan, T., Tan, S., Gao, G., Chen, Y., Abbas, N., Getachew, A., et al. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-0431-y · Cited by 15
Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
Mann, J. P., Carter, P., Armstrong, M. J., Abdelaziz, H. K., Uppal, H., Patel, B., CHANDRAN, S. R., More, R. S., Newsome, P. N., & Potluri, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241357 · Cited by 14
“response to the positive energy balance of obesity, subcutaneous adipose becomes 111 dysfunctional and there is expansion of visceral white adipocytes, which are less insulin 112 sensitive and have a higher basal rate of lipolysis[13].”
Background
Potential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
“NAFLD is associated with obesity, dyslipidemia, hypertension and T2DM, which are clinical features of metabolic syndrome and are associated with insulin resistance and adipose tissue dysfunction [1,9].”
Background
An Extract of Russian Tarragon Prevents Obesity‐Related Ectopic Lipid Accumulation
Yu, Y., Mendoza, T. M., Ribnicky, D., Poulev, A., Noland, R. C., Mynatt, R. L., Raskin, I., Cefalu, W. T., & Floyd, Z. E. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700856 · Cited by 15
Fc Gamma Receptor IIb Expressed in Hepatocytes Promotes Lipid Accumulation and Gluconeogenesis
Shu, T., Song, X., Cui, X., Ge, W., Gao, R., & Wang, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102932 · Cited by 14
“However, knockdown of FcγRIIb significantly resulted in reversions in the OA-induced upregulation of lipogenesis mRNAs compared to their controls (ACC1 and FASn), and lipid transport gene (CD36, MTTP and ApoB), but showed no inhibiting effect on expression of the indicated lipolysis genes (PPARα, CPT1α and MCAD).”
BackgroundInfluential
Association Between Active DNA Demethylation and Liver Fibrosis in Individuals with Metabolic-Associated Steatotic Liver Disease (MASLD)
Barchetta, I., Zampieri, M., Cimini, F. A., Dule, S., Sentinelli, F., Passarella, G., Oldani, A., Karpach, K., Bacalini, M. G., Baroni, M. G., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031271 · Cited by 14
“…liver disease (MASLD) is the most common chronic liver disease worldwide, affecting over 32% of adults globally, and is a critical hepatic component of metabolic dysfunction, closely related to conditions such as obesity, type 2 diabetes mellitus (T2DM), hypertension, and dyslipidemia [1,2].”
Sacubitril/Valsartan partially alleviates myocardial infarction injury by activating the FGF21 signaling pathway via PPARs
Wei, W., Xu, G., Gao, J., Wang, G., Wang, Y., Li, C., Zheng, J.-W., Lu, H., Lu, Y., Wang, K., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02627-6 · Cited by 13
The therapeutic mechanisms of quercetin on inflammatory diseases: an update
Xu, J., Hu, H., Jiang, H., Wei, Q., Zhang, H., & Lu, Q. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01795-x · Cited by 16
“…carcinoma (Eslam et al. 2018) The pathogenesis of NAFLD involves several key mechanisms, including hyperglycemia, oxidative stress, inflammation, insulin resistance, abnormal fatty acid metabolism, and gut microbiota dysbiosis (Chen et al. 2021; Samuel and Shulman 2018; Sotiropoulou et al. 2021).”
Crotonylation of IDH1 alleviates MASLD progression by enhancing the TCA cycle
Liu, S., Ji, Y., Wei, L., Zhang, Y., Zeng, L., Min, Y., Yin, D., Liu, K., Guan, C., Liu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62731-9 · Cited by 13
“The widespread prevalence of MASLD, the attendant risks for metabolic and hepatic complications 8,13 , and the lack of approved therapies are signi ﬁ cant hurdles, but there is no solid and mechanistic founda-tionfortacklingthischallenge.”
Liver MRI–derived Proton Density Fat Fraction Predicts Diabetes Risk in Patients with Obesity: A Dose-Response Study
Deng, M., Li, Z., Sun, L., Wang, H., Tang, J., Liu, Y., Chen, X., Xu, H., & Dai, Z. (2025) · Radiology · doi:10.1148/radiol.250026 · Cited by 13
Ferroptosis and pyroptosis: Mediating mechanisms of the cGAS/STING pathway and therapeutic strategies in heart failure
Zhang, Z., Yang, Z., Wang, S., Wang, X., & Mao, J. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102932 · Cited by 13
ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer
Hong, H., Shao, Y., Zhang, S., Yang, G., Jia, H., Xiao, Y., Huang, L., Li, S., Aikemu, B., Zhang, L., et al. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022121 · Cited by 14
“Acetyl-CoA carboxylase (ACC) is a key and rate-limiting switch in the first step of fatty acid synthesis and metabolism that can catalyze the conversion of acetyl-CoA to malonyl-CoA, playing an important role in the occurrence and development of tumors [14,15].”
Background
The Correlation between Type 2 Diabetes and Fat Fraction in Liver and Pancreas: A Study using MR Dixon Technique
Zheng, Y., Yang, S., Chen, X., Jieqin, L., Su, J., & Yu, S. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/7073647 · Cited by 13
An Overview of Inter-Tissue and Inter-Kingdom Communication Mediated by Extracellular Vesicles in the Regulation of Mammalian Metabolism
Castaño, C., Novials, A., & Párrizas, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032071 · Cited by 14
“Alterations of hepatic physiology caused by a diet enriched in processed food or high-fructose corn syrup can trigger hepatic steatosis that may progress to metabolic dysfunction-associated fatty liver disease (MAFLD), cirrhosis, or even hepatic carcinoma [10].”
Background
Natural deletion of mouse carboxylesterases Ces1c/d/e impacts drug metabolism and metabolic syndrome development
Gan, C., Wang, J., Wang, Y., Martínez-Chávez, A., Hillebrand, M. J. X., de Vries, N., Beukers, J., Lebre, M. C., Wagenaar, E., Rosing, H., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114956 · Cited by 13
Hepatoprotective effect of Typhaneoside on non-alcoholic fatty liver disease via farnesoid X receptor in vivo and in vitro
Zheng, Y., Zhao, J., Miao, D., Xu, T., Wang, L., Liu, C., Gao, Y., Yu, L., & Shen, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114957 · Cited by 13
STE20‐type kinases MST3 and MST4 promote the progression of hepatocellular carcinoma: Evidence from human cell culture and expression profiling of liver biopsies
Caputo, M., Xia, Y., Anand, S. K., Cansby, E., Andersson, E., Marschall, H., Königsrainer, A., Peter, A., & Mahlapuu, M. (2023) · The FASEB Journal · doi:10.1096/fj.202300397rr · Cited by 13
White adipose tissue: Distribution, molecular insights of impaired expandability, and its implication in fatty liver disease
Rabadán-Chávez, G. M., de la Garza, R. I. D., & Jacobo‐Velázquez, D. A. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166853 · Cited by 15
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Gowda, D., Shekhar, C., Gowda, S. G. B., Chen, Y., & Hui, S. (2023) · Livers · doi:10.3390/livers3040045 · Cited by 15
“Targeting abnormal fatty acid and glucose metabolism to stop liver fat accumulation and the creation of a proﬁbrotic environment appear to be promising therapeutic strategies [136,137].”
Untargeted metabolomics based on ultra-high performance liquid chromatography-mass spectrometry/MS reveals the lipid-lowering mechanism of taurine in hyperlipidemia mice
Guo, X., Ou, T., Yang, X., Song, Q., Zhu, L., Mi, S., Zhang, J., Zhang, Y., Chen, W., & Guo, J. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1367589 · Cited by 13
“In a high-fat microenvironment, abnormal intracellular DG increases promoted protein kinase C (PKC) activation (38) and decreased phosphatidylin-ositol-3-kinase (PI3K) activation (34), ultimately leading to insulin resistance.”
Background
Unlocking the potential: very-low-energy ketogenic therapy in obesity-related disorders
Simancas‐Racines, D., Reytor-González, C., Zambrano, A. K., Annunziata, G., Am, C., Verde, L., Frías-Toral, E., Guerra, C. V., & Hidalgo, R. (2025) · Food and Agricultural Immunology · doi:10.1080/09540105.2024.2442368 · Cited by 13
“MASLD is one of the most common liver disorders associated with obesity (Samuel & Shulman, 2018), characterized by the accumulation of fat in the liver that is not related to alcohol consumption.”
Comparison of anthropometric indices for the screening of nonalcoholic fatty liver disease in pre- and postmenopausal women
Hong, S., Hwang, S. Y., Kim, J. A., Lee, Y., Roh, E., Kim, N. H., Seo, J. A., Kim, S. G., Kim, N. H., Choi, K. M., et al. (2019) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001419 · Cited by 13
Serum syndecan‐4 is associated with nonalcoholic fatty liver disease
Xia, S., Tang, L., Li, W. H., Xu, Z. S., Zhang, L. L., Cheng, F. G., Chen, H. X., Wang, Z. H., Luo, Y., Dai, A. N., et al. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13037 · Cited by 13
“The development of NAFLD is closely associated with features of metabolic syndrome.(25) In this study we aimed to investigate the association between serum SDC4 level and NAFLD in a Chinese population.”
Background
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis
Luci, C., Vieira, E., Bourinet, M., Rousseau, D., Bonnafous, S., Patouraux, S., Lefevre, L., Larbret, F., Prod’homme, V., Iannelli, A., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.08.004 · Cited by 14
“Similarly, type 2 diabetes mellitus, insulin resistance, hypertension, and weight gain are risk factors for MAFLD progression.(4,5) However, the inverse relationship also exists, with MAFLD being a risk factor for many metabolic diseases including type 2 diabetes(6) and cardiovascular diseases.”
Background
Six-Transmembrane Epithelial Antigen of Prostate 3 Promotes Hepatic Insulin Resistance and Steatosis
Ding, T., Chen, S., Xiao, W., Liu, Z., Tu, J., Yu, Y., Dong, B., Chen, W., & Zeng, Y. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100318 · Cited by 13
“Fatty liver activates stress-responsive MAPKs such as p38 MAPKs and JNKs (36, 37).”
Background
Clinical features and metabolic complications for non-alcoholic fatty liver disease (NAFLD) in youth with obesity
Barbieri, E., Santoro, N., & Umano, G. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1062341 · Cited by 14
“Early studies by the Shulman lab at Yale University have shown in mice and humans that DAG accumulation impact insulin action in the liver, muscle and adipose tissue, the consequence being higher fasting glucose availability in tissues and plasma (50, 51).”
Background
Liver-breast communication of adipocyte-oriented exosomes drives primary mammary cancer progression
Li, C., Lu, Y., Li, Y., Liu, T., Deng, H. X., Gao, M., Zhou, B., Liu, J., Cai, J., Huang, D., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.08.012 · Cited by 14
Low-Carbohydrate Ketogenic Diet for Improvement of Glycemic Control: Mechanism of Action of Ketosis and Beneficial Effects
Das, S., Sakr, H. F., Sirasanagandla, S. R., Bima, A. I. H., & Elsamanoudy, A. Z. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220511121629 · Cited by 13
Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Lin, R., Zhou, J., Sun, Q., Xin, X., Hu, Y., Zheng, M., & Feng, Q. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17889 · Cited by 12
Evaluation of the hepatotoxicity of Psoralea corylifolia L. based on a zebrafish model
Gao, S.-Y., Zhao, J.-C., Xia, Q., Sun, C., Aili, M., Talifu, A., Huo, S., Zhang, Y., & Li, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1308655 · Cited by 12
ZNF300 stimulates fatty acid oxidation and alleviates hepatosteatosis through regulating PPARα
Yan, F., Wang, Y., Yan, S.-R., Lu, J. L., & Zheng, Y. (2018) · Biochemical Journal · doi:10.1042/bcj20180517 · Cited by 12
Hepatic Knockdown of Endothelin Type A Receptor (ETAR) Ameliorates Hepatic Insulin Resistance and Hyperglycemia Through Suppressing p66Shc-Mediated Mitochondrial Fragmentation in High-Fat Diet-Fed Mice
Li, F., Wang, S., Chen, F., Zhang, C., Wang, Q., Zhao, Y., & Zhang, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s299570 · Cited by 12
“Hepatic steatosis and hyperlipemia increase the supply of gluconeogenic substrate and the generation of mitochondrial acetyl-CoA that is an activator of gluconeogenic enzyme pyruvate carboxylase (PC), promoting hepatic gluconeogenesis and hyperglycemia.(42) In addition, our data showed that hepatic knockdown of ETAR d…”
Background
Discrete Correlation Summation Clustering Reveals Differential Regulation of Liver Metabolism by Thrombospondin-1 in Low-Fat and High-Fat Diet-Fed Mice
Bronson, S. M., Westwood, B. M., Cook, K. L., Emenaker, N. J., Chappell, M. C., Roberts, D. D., & Soto‐Pantoja, D. R. (2022) · Metabolites · doi:10.3390/metabo12111036 · Cited by 12
“The progression of NAFLD is often associated with global and hepatic insulin resistance, which alters hepatic gluconeogenesis and glucose flux [40].”
Background
Hepatic‐Targeted Nano‐enzyme with Resveratrol Loading for Precise Relief of Nonalcoholic Steatohepatitis
Tong, Y., Yu, X., Huang, Y., Zhang, Z., Mi, L., & Bao, Z. (2022) · ChemMedChem · doi:10.1002/cmdc.202200468 · Cited by 12

Authors: Samuel, V. T., & Shulman, G. I.
Affiliations: United States Department of Veterans Affairs (US)
Howard Hughes Medical Institute (US)
Corresponding author: Samuel, Varman T.
Shulman, Gerald I.
ORCID: Samuel, Varman T.
Shulman, Gerald I.
Venue: Cell Metabolism
Publisher: Elsevier BV
Published: 2018-01
Volume: 27
Issue: 1
Pages: 22-41
ISSN: 1550-4131 (ISSN-L)
DOI: 10.1016/j.cmet.2017.08.002
PMC: PMC5762395
OpenAlex: W2752428556
Cited by: 745
References: 263
Citations by year: 2026: 72 · 2025: 84 · 2024: 90 · 2023: 109 · 2022: 88 · 2021: 91 · 2020: 81 · 2019: 71 · 2018: 50
FWCI: 7.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 374 d)
Locations: Cell Metabolism (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Celgene
Novo Nordisk
National Institutes of Health (DK-40936, DK-45735, DK-R01 DK 11398401)
AstraZeneca
Gilead Sciences
Merck
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: non-alcoholic fatty liver disease, hepatic insulin resistance, diacylglycerol, protein kinase C epsilon, insulin receptor, glycogen synthesis, lipogenesis, gluconeogenesis, pyruvate carboxylase, bariatric surgery, weight loss, PPAR agonists, farnesoid X receptor, FGF21, glucagon-like peptide-1, acetyl-CoA carboxylase, stearoyl-CoA desaturase, mitochondrial uncoupling, therapeutic target
MeSH terms: Animals, Glucose, Humans, Insulin, Insulin Resistance, Metabolic Diseases, Lipid Metabolism, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks